艾瑞昔布联合甲氨蝶呤+硫酸羟氯喹治疗类风湿关节炎的疗效分析

Analysis of the Curative Effect of Irecoxib Combined with Methotrexate+Hydroxychloroquine Sulfate in the Treatment of Rheumatoid Arthritis

目的分析艾瑞昔布联合甲氨蝶呤+硫酸羟氯喹治疗类风湿关节炎(RA)的疗效。方法方便选取2018年5月—2019年12月在该院进行治疗的66例RA患者,根据不同治疗方法分为对照组与观察组,两组均进行甲氨蝶呤+硫酸羟氯喹用药,对照组另添加塞来昔布用药,观察组另添加艾瑞昔布用药,对比两组患者治疗后恢复情况。结果对照组与观察组的疗效率分别为90.91%、96.97%,差异无统计学意义(χ^(2)=0.266,P>0.05);治疗后,对照组晨僵时长(1.14±0.49)h、关节肿胀数(5.18±1.96)个、关节疼痛数(4.52±3.43)个、红细胞沉降率(ESR)(32.13±18.41)mm/h、C反应蛋白(CRP)(25.19±15.86)mg/L、视觉模拟评分(VAS)(3.50±0.55)分、疾病活动性评分系统(DAS28)(2.71±0.25)分与观察组晨僵时长(1.12±0.36)h、关节肿胀数(5.15±1.98)个、关节疼痛数(4.47±2.28)个、ESR(31.35±18.22)mm/h、CRP(25.11±15.67)mg/L、VAS(3.48±0.51)分、DAS28(2.68±0.24)分相比,差异无统计学意义(t=0.189、0.062、0.070、0.173、0.021、0.153、0.497,P>0.05)。对照组与观察组不良反应总发生率分别为15.15%、18.18%,差异无统计学意义(χ^(2)=0.266,P>0.05)。结论艾瑞昔布、塞来昔布分别联合甲氨蝶呤+硫酸羟氯喹治疗RA的疗效相当,不良反应都较少,且艾瑞昔布为我国自主研发新药,具有临床进一步推广意义。

Objective To analyze the curative effect of imrecoxib combined with methotrexate and hydroxychloroquine sulfate on rheumatoid arthritis(RA).Methods Convenient select A total of 66 RA patients treated in the hospital from May 2018 to December 2019 were enrolled and divided into control group and observation group according to different treatment methods.Both groups were treated with methotrexate and hydroxychloroquine sulfate.On this basis,control group was treated with celecoxib,while observation group was treated with imrecoxib.The recovery after treatment was compared between the two groups.Results The efficacy rates of the control group and the observation group were 90.91%and 96.97%,respectively,the difference was not statistically significant(χ^(2)=0.266,P>0.05).After treatment,In the control group,morning stiffness time(1.14±0.49)h,joint swelling number(5.18±1.96),joint pain number(4.52±3.43),erythrocyte sedimentation rate(ESR)(32.13±18.41)mm/h,C-reactive protein(CRP)(25.19±15.86)mg/L,visual simulation score VAS(3.50±0.55)points,DAS28(2.71±0.25)points,compared with the morning stiffness time(1.12±0.36)h,joint swelling number(5.15±1.98),joint pain number(4.47±2.28),ESR(31.35±18.22)mm/h,CRP(25.11±15.67)mg/L,VAS(3.48±0.51)points,DAS28(2.68±0.24)points in the observation group,the differenc was not statistically significant(t=0.189,0.062,0.070,0.173,0.021,0.153,0.497,P>0.05).The total incidence of side effects in the control group and the observation group was 15.15%and 18.18%,respectively,the difference was not statistically significant(χ^(2)=0.266,P>0.05).Conclusion On basis of methotrexate combined with hydroxychloroquine sulfate,curative effect of imrecoxib and celecoxib is comparable on RA,with fewer adverse reactions.Imrecoxib is a new drug independently developed in my country,which is of further clinical promotion significance.